MAÜ GCRIS Standart veritabanının içerik oluşturulması ve kurulumu Research Ecosystems (https://www.researchecosystems.com) tarafından devam etmektedir. Bu süreçte gördüğünüz verilerde eksikler olabilir.

Fizyoloji Anabilim Dalı Koleksiyonu

Permanent URI for this collectionhttps://hdl.handle.net/20.500.12514/4220

Browse

Browsing Fizyoloji Anabilim Dalı Koleksiyonu by Author "Gökdemir, Mehmet Tahir"

Filter results by typing the first few letters
Now showing 1 - 3 of 3
  • Thumbnail Image
    Article
    EFFECT OF METFORMIN ON MUSCLE ATROPHY IN EXPERIMENTAL DIABETIC RATS
    (2023) Gökdemir, Gül Şahika; Gökdemir, Mehmet Tahir; Gökdemir, Mehmet Tahir; Baylan,Mukadder
    Background: Although first-line biguanide metformin is frequently administered to T2DM patients, the effects of long-term use on muscle are unknown. This study aimed to examine the effect of metformin-treated diabetes on muscle atrophy in experimental diabetic rats. Materials and methods: Twenty-one Wistar albino male rats in 3 groups were included in our research. Insulin resistance HOMA-IR, mTOR, and Myostatin levels and gastrocnemius weight were measured. Results: Myostatin level was significantly higher in the non-medicated diabetes group than in the healthy control group (p<0.001). Moreover, myostatin level was significantly lower in the metformin group (p=0.001). The weight of gastrocnemius was significantly lower in both the metformin-treated and non-metformin-treated diabetic groups compared to the control group (p<0.001 for both groups). Moreover, the gastrocnemius weight was significantly higher in the metformin group than in the non-medicated group (p=0.004). The HOME-IR level had a significantly negative correlation with the mTOR level (R=-0.783; P<0.001) and a positive correlation with the myostatin level (R=0.622; P=0.003). Conclusion: Our evidence and data support that metformin may be effective in preventing muscle wasting. To conclude, this study showed that metformin has anti-atrophic effects on muscles in diabetes and that metformin can prevent muscle mass loss.
  • Thumbnail Image
    Article
    Importance of Curcumin Effect and Asprosin Level on Glucose Metabolism in Diabetic Rats
    (2023) Gökdemir, Gül Şahika; Atmaca, Mukadder; Gokdemir, Gul Sahika; Gökdemir, Mehmet Tahir; Gökdemir, Mehmet Tahir; Taşdemir, Ezel; Yokus, Beran
    Asprosin is a new hormone secreted mainly from white adipose tissue. It may be associated with the pathogenesis of obesity, diabetes and some metabolic diseases. The changes in plasma asprosin levels of experimental diabetic rats and the relation of these changes with liver glucose metabolism and some diabetes parameters were investigated, and the effects of metformin, gliclazide or curcumin treatment on plasma asprosin levels were tried. The study was designed as an animal model in diabetic rats The albino rats were divided into five groups. To induce diabetes, a single dose of STZ was injected intraperitoneally. Diabetics rats were treated intragastrically with metformin (D+Metformin group), gliclazide (D+Giliclazide group) or 20 curcumin (D+Curcumin group) for eight weeks. Fasting blood glucose, insulin levels and other parameters were measured. Plasma asporsin levels of untreated diabetic rats increased significantly (P<.001). Although the plasma asprosin levels of diabetic rats treated with the rugs were significantly lower (P<.001). Fasting blood glucose levels of diabetic rats treated with the drugs were found to be remarkably lower than the diabetic control values (P<.001, respectively). There was no significant difference in the insulin levels and HOMA- IR between these three groups. Curcumin treatment provides significant improvements in plasma asprosin level and diabetes parameters. The increase in plasma asprosin level in diabetic rats may be one of the main reasons that facilitate the development of the disease or is responsible for its pathogenesis. Our findings support the idea that curcumin may be an important treatment option for diabetes.
  • Thumbnail Image
    Article
    Prognostic significance of the chemerin level in coronavirus disease 2019 patients
    (Lippincott Williams & Wilkins, 2024) Gökdemir, Gül Şahika; Gokdemir, Guel Sahika; Gokdemir, Mehmet Tahir; Gökdemir, Mehmet Tahir; Arac, Songul; Yokus, Beran
    Increased serum chemerin levels have been reported in several inflammatory diseases. Few studies have investigated the relationship between chemerin and clinical features of COVID-19. Thus, chemerin may modulate the development and progression of COVID-19. We compared the serum chemerin concentration between patients with and without SARS-CoV-2 infection and its association with the severity and prognosis of COVID-19 pneumonia. This is a prospective, single-center, cross-sectional study. We enrolled COVID-19 patients who presented to our tertiary hospital and healthy controls. The COVID-19 patients were conducted and the dates of symptom onset were recorded. After admission to the hospital and stabilization, blood samples were obtained for routine hemogram, biochemistry, and chemerin. The chemerin level was 37.93 +/- 17.3 ng/mL in patients followed in the ICU, 29.41 +/- 12.79 ng/mL in inpatients, 30.48 +/- 10.86 ng/mL in outpatients, and 25.12 +/- 9.82 ng/mL in healthy controls. The difference between patients treated in the ICU and healthy controls was significant (P < .001). The high-sensitivity C-reactive protein (hs-CRP), ferritin, procalcitonin (PCT), and D-dimer levels were significantly higher in the intensive care unit (ICU) group (P < .001). Moreover, the chemerin level of patients who died was significantly higher than that of those who survived (P < .001). The chemerin level was increased in COVID-19 patients and also increased with increasing disease severity. The chemerin level was higher in the COVID-19 patients than healthy controls and was significantly higher in patients who died compared to those who did not.